MGCD-0103. Histone deacetylase inhibitor, apoptosis inducer, oncolytic

Drugs of the Future

Volumn 33, Issue 4, 2008, Pages 323-327

  Kell, J ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BELINOSTAT; DOCETAXEL; GEMCITABINE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; ROMIDEPSIN; SNDX 275; VORINOSTAT;

ABDOMINAL PAIN; ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANOREXIA; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CYCLE REGULATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL TUMOR; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FATIGUE; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE MUTATION; HODGKIN DISEASE; HUMAN; KIDNEY TUMOR; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CARCINOMA; PNEUMONIA; PROSTATE CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 45949111822     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.04.1189133     Document Type: Article

References (40)

1. Delorme, D., Zhou, Z. (MethylGene, Inc.). Inhibitors of histone deacetylase. EP 1590340, JP 2006514998, US 2004142953, US 6897220, WO 2004069823.
2. Peterson, C.L., Laniel, M.A., Peterson, C.L., Laniel, M.A. Histones and histone modifications. Curr Biol 2004, 14(14): R546-51.
3. Fraga, M.F., Ballestar, E., Villar-Garea, A. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37(4): 391-400.
4. Johnson, C.A., White, D.A., Lavender, J.S., O'Neill, L.P. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J Biol Chem 2002, 277(11): 9590-7.
5. Bali, P., Pranpat, M., Bradner, J. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J Biol Chem 2005, 280(29): 26729-34.
6. Yoshida, M., Matsuyama, A., Komatsu, Y. et al. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 2003, 10(22): 2351-8.
7. Merck & Co.'s Zolinza approved by FDA for CTCL. Merck & Co., Inc. Press Release, October 8, 2006.
8. Suberoylanilide hydroxamic acid (SAHA) versus placebo in advanced malignant pleural mesothelioma (NCT00128102). ClinicalTrials.gov Web site, February 25, 2008.
9. Tsuji, N., Kobayashi, M., Nagashima, K. et al. A new antifungal antibiotic, trichostatin. J Antibiot 1976, 29(1): 1-6.
10. Qian, X., Ara, G., Mills, E., LaRochelle, W.J., Lichenstein, H.S., Jeffers, M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 2008, 122(6): 1400-10.
11. Gloucester Pharmaceuticals reports clinically significant responses in pivotal trial of romidepsin for cutaneous T-cell lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting. Gloucester Pharmaceuticals, Inc. Press Release, December 10, 2007.
12. MethylGene and Pharmion announce U.S. orphan drug designation granted by the FDA for MGCD0103 for the treatment of acute myelogenous leukemia (AML). MethylGene, Inc. Press Release, February 14, 2008.
13. Vaisburg, A. Discovery and development of MGCD-0103 - An orally active HDAC inhibitor in human clinical trials. Drugs Fut 2006, 31(Suppl. A): Abst L57.
14. Li, Z., Zhou, N., Fournel, M. et al. Antitumor activities of MGCD0103, a novel isotype-selective histone deacteylase inhibitor. Eur J Cancer - Suppl 2004, 2(8): Abst 83.
15. Maroun, C., Liu, J., Kalita, A. et al. Induction of interleukin-6 expression by the histone deacetylase inhibitor, MGCD0103, in leukemia patients in vivo correlates with clinical efficacy. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 1831.
16. Bonfils, C., Kalita, A., Liu, J., Besterman, J.M., Li, Z. Development of whole cell HDAC enzyme assay to analyze inhibitory activity of MGCD0103 in vitro and in vivo. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 606.
17. Nguyen, H., Gravel, S., MacLeod, R. Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C220.
18. Garcia-Manero, G., Minden, M., Estrov, Z. et al. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS). J Clin Oncol 2006, 24(18, Suppl.): Abst 6500.
19. Siu, L.L., Carducci, M., Pearce, L. et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst C77.
20. Garcia-Manero, G., Minden, M., Estrov, Z. et al. A phase I study of the histone deacetylase inhibitor MGCD0103 (MG-0103) given as a three-times weekly oral dose in patients with leukemia or myelodysplastic syndromes (MDS). Blood 2005, 106(11): Abst 4639.
21. Lancet, J.E., Nichols, G., Assouline, S. et al. A phase 1 study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS). Blood 2006, 108(11): Abst 1971.5.
22. Carducci, M., Siu, L.L., Sullivan, R. et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 3007.
23. Kalita, A., Maroun, C., Bonfils, C. et al. Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin's lymphoma (NHL). 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 9631.
24. Gelmon, K., Tolcher, A., Carducci, M. et al. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3147.
25. Siu, L.L., Carducci, M., Chen, E.X. et al. Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors. Eur J Cancer - Suppl 2006, 4(12): Abst 300.
26. MGCD0103 in elderly patients with previously untreated AML/high risk MDS or adults with relapsed/refractory disease (NCT00374296). ClinicalTrials.gov Web site, February 27, 2008.
27. A phase I study of MGCD0103 given three-times weekly in patients with leukemia or myelodysplastic syndromes (NCT00324129). ClinicalTrials.gov Web site, February 27, 2008.
28. A phase I study of MGCD0103 given twice weekly in patients with leukemia or myelodysplastic syndromes (NCT00324194). ClinicalTrials.gov Web site, February 27, 2008.
29. Study of MGCD0103 (MG-0103) in patients with relapsed or refractory Hodgkin's lymphoma (NCT00358982). ClinicalTrials.gov Web site, February 27, 2008.
30. Study of MGCD0103 given three times weekly in patients with relapsed and refractory lymphoma (NCT00359086). ClinicalTrials.gov Web site, February 27, 2008.
31. A phase II study of MGCD0103 (MG-0103) in patients with refractory chronic lymphocytic leukemia (NCT00431873). ClinicalTrials.gov Web site, February 27, 2008.
32. A phase I/II study of MGCD0103 with azacitidine in patients with high-risk MDS or acute myelogenous leukemia (NCT00324220). ClinicalTrials.gov Web site, February 27, 2008.
33. MGCD0103 administered in combination with azacitidine (Vidaza®) to subjects with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma (NCT00543582). ClinicalTrials.gov Web site, February 27, 2008.
34. Study to evaluate combination treatment of MGCD0103 and docetaxel (Taxotere®) for subjects with advanced cancer tumors (NCT00511576). ClinicalTrials.gov Web site, February 27, 2008.
35. A phase I/II study of MGCD0103 (MG-0103) in combination with gemcitabine (NCT00372437). ClinicalTrials.gov Web site, February 27, 2008.
36. Garcia-Manero, G., Yang, A.S., Klimek, V. et al. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). J Clin Oncol 2007, 25(18, Suppl.): Abst 7062.
37. Garcia-Manero, G., Yang, A.S., Klimek, V. et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 444.
38. Younes, A., Pro, B., Fanale, M. et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 2566.
39. Younes, A., Pro, B., Fanale, M. et al. A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Haematologica [7th Int Symp Hodgkin Lymphoma (Nov 3-7, Cologne) 2007] 2007, 92(Suppl. 5): Abst C014.
40. Younes, A., Wedgwood, A., McLaughlin, P. et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. Blood [49th Annu Meet Am Soc Hematol (Dec 8-11, Atlanta) 2007] 2007, 110(11): Abst 2571.